HISTOLOGIC CORRELATES OF PROGRESSION-FREE INTERVAL AND SURVIVAL IN OVARIAN CLEAR-CELL ADENOCARCINOMA

被引:27
作者
KENNEDY, AW [1 ]
BISCOTTI, CV [1 ]
HART, WR [1 ]
TUASON, LJ [1 ]
机构
[1] CLEVELAND CLIN EDUC FDN,DEPT ANAT PATHOL & BIOSTAT,CLEVELAND,OH 44106
关键词
D O I
10.1006/gyno.1993.1221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Unlike other ovarian epithelial cancers, histologic measures of differentiation of ovarian clear cell adenocarcinoma have not been found to be reliable predictors of progression-free interval and survival. Forty-two consecutively treated patients with pure ovarian clear cell adenocarcinoma were identified and all histologic materials were reviewed. The following histologic features were assessed: architectural pattern (tubular/tubulocystic, papillary, solid, and mixed), average and maximal mitotic activity per 10 high-power fields (hpf’s), percentage of cells with clear cytoplasm, and nuclear grading (both Fuhrman et al.’s (Am. J. Surg. Pathol. 6, 655-663, 1982) and Christopherson et al.’s (Cancer 49, 1511-1523, 1982) methods). Surgical stage was most predictive of survival (P < 0.01) and subsequent comparisons using Cox proportional hazards modeling were adjusted for Stages III and IV. Greater than six mitotic figures per 10 hpf’s predicted a poorer survival (P = 0.05) but was not predictive of progression- free interval (P = 0.28). Survival and progression-free interval in patients with tumors of mixed architectural pattern tended to be shorter than those for patients where one type did predominate, but this was not statistically significant (P = 0.06). The tubulocystic pattern was not predictive of patient outcome nor was either method of nuclear grading. Stage and average mitotic activity seem to be the best predictors of survival for patients with ovarian clear cell adenocarcinoma, while architectural pattern and nuclear grading are not as reliable. © 1993 Academic Press, Inc.
引用
收藏
页码:334 / 338
页数:5
相关论文
共 18 条
[1]  
AURE JC, 1971, OBSTET GYNECOL, V37, P860
[2]  
CHRISTOPHERSON W M, 1982, Cancer, V49, P1511, DOI 10.1002/1097-0142(19820415)49:8<1511::AID-CNCR2820490802>3.0.CO
[3]  
2-6
[4]   CLEAR CELL-CARCINOMA OF THE OVARY - A STUDY OF 59 CASES [J].
CROZIER, MA ;
COPELAND, LJ ;
SILVA, EG ;
GERSHENSON, DM ;
STRINGER, CA .
GYNECOLOGIC ONCOLOGY, 1989, 35 (02) :199-203
[5]   PROGNOSTIC-SIGNIFICANCE OF MORPHOLOGIC PARAMETERS IN RENAL-CELL CARCINOMA [J].
FUHRMAN, SA ;
LASKY, LC ;
LIMAS, C .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (07) :655-663
[6]  
HERBST AL, 1980, AM J OBSTET GYNECOL, V135, P876
[7]   THE INFLUENCE OF CYTOREDUCTIVE SURGERY ON RECURRENCE-FREE INTERVAL AND SURVIVAL IN SMALL-VOLUME STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
HOSKINS, WJ ;
BUNDY, BN ;
THIGPEN, JT ;
OMURA, GA .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :159-166
[8]   CLEAR CELL ADENOCARCINOMA OF THE OVARY - A CLINICAL ANALYSIS AND COMPARISON WITH SEROUS CARCINOMA [J].
JENISON, EL ;
MONTAG, AG ;
GRIFFITHS, CT ;
WELCH, WR ;
LAVIN, PT ;
GREER, J ;
KNAPP, RC .
GYNECOLOGIC ONCOLOGY, 1989, 32 (01) :65-71
[9]   OVARIAN CLEAR CELL ADENOCARCINOMA [J].
KENNEDY, AW ;
BISCOTTI, CV ;
HART, WR ;
WEBSTER, KD .
GYNECOLOGIC ONCOLOGY, 1989, 32 (03) :342-349
[10]   SURGERY WITHOUT ADJUVANT CHEMOTHERAPY FOR EARLY EPITHELIAL OVARIAN-CARCINOMA AFTER COMPREHENSIVE SURGICAL STAGING [J].
MONGA, M ;
CARMICHAEL, JA ;
SHELLEY, WE ;
KIRK, ME ;
KREPART, GV ;
JEFFREY, JF ;
PATER, JL .
GYNECOLOGIC ONCOLOGY, 1991, 43 (03) :195-197